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Abstract
Background There is very limited evidence examining serious systemic adverse events (SSAEs) and post-injection endoph-
thalmitis of intravitreal bevacizumab (IVB) and intravitreal ranibizumab (IVR) treatments in Thailand and low- and middle-
income countries. Moreover, findings from the existing trials might have limited generalizability to certain populations and 
rare SSAEs.
Objectives This prospective observational study aimed to assess and compare the safety profiles of IVB and IVR in patients 
with retinal diseases in Thailand.
Methods Between 2013 and 2015, 6354 patients eligible for IVB or IVR were recruited from eight hospitals. Main outcomes 
measures were prevalence and risk of SSAEs, mortality, and endophthalmitis during the 6-month follow-up period.
Results In the IVB and IVR groups, 94 and 6% of patients participated, respectively. The rates of outcomes in the IVB group 
were slightly greater than in the IVR group. All-cause mortality rates in the IVB and IVR groups were 1.10 and 0.53%, 
respectively. Prevalence rates of endophthalmitis and non-fatal strokes in the IVB group were 0.04% of 16,421 injections 
and 0.27% of 5975 patients, respectively, whereas none of these events were identified in the IVR group. There were no dif-
ferences between the two groups in the risks of mortality, arteriothrombotic events (ATE), and non-fatal heart failure (HF). 
Adjustment for potential confounding factors and selection bias using multivariable models for time-to-event outcomes and 
propensity scores did not alter the results.
Conclusions The rates of SAEs in both groups were low. The IVB and IVR treatments were not associated with significant 
risks of mortality, ATE, and non-fatal HF.
Trial Registration Thai Clinical Trial Registry identifier TCTR20141002001.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4026 1-018-0678-5) contains 
supplementary material, which is available to authorized users.
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Key Points 
Safety evidence of IVB and IVR derived from rand-
omized controlled trials and studies in other settings 
might not be generalizable to the Thai population in 
routine clinical practice.
This is the first large prospective observational study 
examining the safety of IVB compared with IVR 
in Thailand and low- and middle-income countries 
(LMICs) where there is a lack of appropriate infrastruc-
ture for repackaging the pre-filled bevacizumab syringes 
compared to high-income countries.
This study found low rates of pre-specified serious 
systemic adverse events and endophthalmitis, which 
are consistent with the studies conducted in developed 
countries in terms of the short-term safety profiles of 
IVB and IVR
1 Introduction
Many retinal diseases are leading causes of visual disability 
worldwide [1, 2]. The global pooled prevalence estimates 
derived from population-based studies for age-related macu-
lar degeneration (AMD), diabetic macular edema (DME), 
and retinal vein occlusion (RVO) were 8.69% of people aged 
30–97 years [3], 7.48% of diabetic patients aged 20–79 years 
[4], and 0.52% of people worldwide [5], respectively. The 
rapid growth of an aging population and the rising impact 
of non-communicable diseases have led to a substantial 
increase in the number of patients suffering from these reti-
nal disorders. Asia is the most populous continent in the 
world, and it was estimated that nearly one-third of patients 
affected by AMD will reside in this region by 2040 [3]. Poor 
vision from central vision loss leads to devastating conse-
quences for the affected patients, their families, and society 
in terms of economic burden, quality of life, carrying out 
daily activities, including work, and psychosocial impacts 
[6–8]. Access to effective treatments in a timely manner is 
crucial to counteract the burden of visual loss due to such 
diseases.
During the past decade, vascular endothelial growth 
factor (VEGF) inhibitors have played an essential role in 
preserving and restoring visual impairment from a vari-
ety of retinal conditions. The off-label use of intravitreal 
bevacizumab (IVB) was prevalent before ranibizumab was 
licensed for nAMD in 2006 [9]. Moreover, limited access 
to intravitreal ranibizumab (IVR) therapy due to its high 
cost has driven the off-label use of IVB in many countries 
[10–12]. In Thai public hospitals, the cost of a single dose of 
ranibizumab was US$1371 (the reference price in 2015 from 
the Drug and Medical Supply Information Center, Thailand) 
while the minimum cost of pre-filled bevacizumab syringes 
for intravitreal injections (IVT) was approximately US$23.
Improper compounding procedures in repackaged beva-
cizumab for IVT have been associated with microbial con-
tamination causing post-injection endophthalmitis outbreaks 
[13–15]. This issue is problematic, particularly among 
low- and middle-income countries (LMICs) where there is 
a lack of appropriate infrastructure for repackaging the pre-
filled syringes compared to high-income countries (HICs). 
Another concern [which has been reported from the use of 
intravenous (IV) bevacizumab for cancer treatments] is the 
occurrence of rare serious systemic adverse events (SSAEs) 
in relation to its ability to inhibit the VEGF pathway, nota-
bly thromboembolic events [16–21]. A possible association 
between anti-VEGF therapy and SSAEs, particularly the 
risks of arterial thromboembolic events (ATEs), systemic 
hemorrhage, heart failure (HF), venous thromboembolism 
(VTE), hypertension (HT), and vascular death, has been 
raised [22]. However, previous studies [16, 17, 23, 24] found 
no statistically significant differences between the IVB and 
IVR therapies in terms of the occurrence of these SSAEs, 
including ATEs and death. Even though IVB is considered 
to be comparable to IVR in terms of effectiveness and safety 
for ocular treatment [10, 12, 19, 22, 25–30] at a much lower 
price, difficulties have arisen from its off-label use from a 
legal aspect when the licensed drug is available [31, 32], and 
debates over the validity and methodological limitations of 
existing drug safety evidence [16, 17, 23, 33].
Most Thai people are eligible for necessary health ser-
vices according to the three main national health insurance 
(NHI) schemes under the universal health coverage policy: 
the Civil Servant Medical Benefit Scheme (CSMBS), the 
Universal Coverage scheme (UC), and the Social Security 
Scheme (SSS) [34]. The CSMBS—which provides health-
care benefits to government employees and their dependents, 
and retirees, and comprises approximately 8% of the Thai 
population—has a policy which restricts reimbursement 
for off-label medicines. Therefore, ranibizumab, which was 
the only FDA-approved anti-VEGF drug for ophthalmic 
indications available and licensed in 2007, was included in 
the benefit package of the CSMBS. As a result, CSMBS 
beneficiaries had access to high-priced IVR free of charge. 
However, none of the anti-VEGF drugs were listed in the 
National List of Essential Medicines (NLEM) for patients 
with retinal diseases in the other NHI schemes (the UC and 
SSS) prior to 2012.
Comparative effectiveness research [19] showed that IVB 
and IVR had equal efficacy for treatments of neovascular 
age-related macular degeneration (nAMD) and DME, but 
safety was inconclusive due to insufficient evidence. Based 
on the findings of this study, the multiple-stakeholder panel 
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suggested that ranibizumab was the preferable choice if the 
producer agreed to reduce the price; otherwise, the subcom-
mittee of the NLEM should include bevacizumab instead 
of ranibizumab and develop a drug safety monitoring sys-
tem instead. Subsequently, in 2012, IVB was included in 
the NLEM for treating nAMD and DME after negotiations 
to reduce the price of ranibizumab failed [35]. Since then, 
access to IVB therapy for nAMD and DME for Thai benefi-
ciaries under the UC and SSS, which represents 92% of the 
Thai population, has been enhanced. Eight months after the 
policy action on the off-label use of IVB in Thailand, IVB 
was listed in a complementary list of the 18th WHO Model 
List of Essential Medicines (EML) for nAMD [36]. This 
decision was made taking into consideration the available 
evidence of benefit-risk profiles between IVB and IVR, and 
public health need for affordable nAMD treatment.
Evidence assessing the safety of pre-filled syringes of 
bevacizumab for macular disease treatment in LMICs and 
Thailand was scarce. Additionally, there was limited evi-
dence comparing the risks of serious adverse events (SAEs) 
between IVB and IVR treatments to support policy deci-
sion making. A few studies [37–39] were conducted in the 
Thai setting to assess the safety of IVB and IVR. All were 
retrospective medical chart reviews with small sample sizes. 
Thus, this team opted to determine the safety of these drugs 
in real-world settings and to supplement findings from previ-
ous randomized controlled trials (RCTs), which had limited 
generalizability.
Therefore, the study aimed to determine the prevalence of 
SAEs of interest and to compare those risks between patients 
treated with IVB and IVR using real-life data from the Thai 
clinical setting.
2  Methods
2.1  Study Design
This study was designed as a prospective, multicenter, obser-
vational study conducted in patients with retinal vascular 
diseases who underwent either IVB (1.25 mg/0.05 mL) or 
IVR (0.5 mg/0.05 mL) treatments. Using convenience sam-
pling [40], participants were followed up for 6 months after 
enrollment where each person underwent ocular examina-
tions and treatments according to routine clinical practices. 
This study was registered with the Thai Clinical Trials Reg-
istry (TCTR20141002001).
2.2  Study Setting and Participants
This study started a few months after the initiation of reim-
bursing IVB for patients with nAMD and DME under 
the NLEM policy. Patients with retinal diseases were 
prospectively recruited from the outpatient ophthalmol-
ogy clinics of eight tertiary and teaching hospitals located 
in Central, Northern, and North-eastern Thailand between 
January 2013 and August 2014. These medical centers were 
chosen for their capacity to diagnose and treat retinal disor-
ders with IVB and IVR; this included diagnostic equipment 
such as fundus fluorescein angiography (FFA) and optical 
coherence tomography (OCT), operating theatres, experi-
enced retinal specialists, and other physicians who could 
deal with any complications arising from retinal diseases 
or anti-VEGF therapy. The pharmacy department in each 
hospital was responsible for the repackaging of IVB in bulk 
in laminar flow clean rooms using sterile techniques, as with 
drugs for intravenous injection or cytotoxic drugs. Contain-
ers were labelled with drug name, dates of preparation and 
expiration, preparation lot number, shelf-life, and storage 
condition. These prefilled syringes were refrigerated before 
administration and containers with ice or gel packs were 
used during the drug transfer. The repackaged bevacizumab 
must be used in 14 to 30 days, as indicated on the label.
2.2.1  Inclusion Criteria
Regardless of sex, patients aged ≥ 18 years who were either 
IVB- or IVR-naïve or had previously received IVB or IVR 
treatment for retinal pathologies, were eligible to participate. 
All participants were required to provide written informed 
consent at the time of enrollment.
2.2.2  Exclusion Criteria
Patients were excluded from the study if they had been 
treated with IVB within the 6 months prior to participation 
in the IVR-treated group at enrollment, and vice versa. This 
ensured that there was no interference effect from the other 
drug.
A safety analysis was performed only on datasets from 
participants with at least one post-baseline assessment.
2.3  Data Collection
Patient interviews and medical record reviews were con-
ducted at least once a month for a period of 6 months. Safety 
checks were performed via telephone calls when patients 
missed scheduled clinic visits for longer than a month to ask 
if they had experienced any SAEs since the previous visit. 
These patient data were documented in the designed paper 
case report forms (pCRFs). Afterwards, the pCRFs were 
reviewed and corrected to ensure accuracy and complete-
ness before undergoing independent double data entry and 
data validation. Any discrepancies in the database, particu-
larly key baseline characteristics and diagnosis of events of 
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interest, were reconciled against the original pCRFs or medi-
cal records; a third party was used if necessary.
We also used data from the two national databases. 
The National Health Security Office (NHSO)’s in-patient 
database provides hospital admission data of beneficiaries 
under the three NHI schemes—which cover more than 90% 
of all admissions from public hospitals and contracted pri-
vate hospitals in Thailand. The other source of data from 
the Bureau of Health Policy and Strategy (BPS), Ministry 
of Public Health was used to obtain the mortality data of 
Thai citizens from the Ministry of Interior’s civil registra-
tion database. The data from these two databases helped 
to identify hospitalization due to SAEs, or death occurring 
at hospitals outside of our study sites as well as death out-
side of hospitals during the follow-up period for all patients, 
including those who were lost to follow-up. The medical 
records of in-hospital deaths were independently reviewed 
by two physicians to verify causes of death; possible dis-
crepancies were resolved by a third physician. When deaths 
could not be verified due to insufficient information or lack 
of access to medical records, the cause of death as indicated 
in the death certificate was applied.
2.4  Variables, Interventions Exposures, 
and Outcomes
At the enrollment date, demographic and socioeconomic 
data, comorbidities, relevant medical history, smoking sta-
tus, concomitant anticoagulant and antiplatelet therapies, 
history of IVB or IVR treatment, indication for IVB or IVR 
therapy, and ocular assessments were recorded as baseline 
characteristics. Since the selection of health interventions 
of each patient in Thai public hospitals relies heavily on 
the NHI scheme rather than other socioeconomic factors, 
we used the NHI scheme as a covariate representing the 
socioeconomic status (SES) of patients and categorized it 
into CSMBS and non-CSMBS (included the UC and the 
SSS subgroups).
Treatment information, such as the number of treated 
eyes, number of IVR and IVB injections, timing of each 
injection, use of topical antibiotics after IVT, room for IVT 
administration (i.e. operating room or other rooms), date and 
lot number of repackaged bevacizumab for ocular use, and 
IVT of other drugs, were recorded.
Primary outcomes of interest were the prevalence rates of 
non-fatal strokes and endophthalmitis in the group receiving 
IVB. Secondary outcomes were SSAEs proposed by previ-
ous studies, which included non-fatal ischemic heart dis-
ease (IHD) or myocardial infarction (MI), ATE, VTE, HF, 
transient ischemic attack (TIA), gastrointestinal (GI) hem-
orrhage or perforation, all-cause mortality, and death from 
vascular-related causes. ATE was defined as the occurrence 
of a non-fatal stroke, non-fatal MI or IHD. Vascular death 
included deaths after a stroke, MI/IHD, or cardiac arrest, and 
VTE comprised pulmonary embolism (PE) and deep vein 
thrombosis (DVT) [41].
2.5  Statistical Analysis
Descriptive statistics was used to describe demographics, 
baseline characteristics, and safety outcomes; the mean and 
standard deviations (SD) were used for continuous variables. 
Frequencies and percentages were used for describing cat-
egorical variables. The unit of analysis for SSAEs was per 
person, while the rate of ocular SAEs was reported as per 
total patients, total treated-eyes, and total drug injections.
For SSAEs, incidence rates were calculated with event-
free probabilities and were illustrated as Kaplan–Meier 
(K–M) curves (Online Resource 1). Data about individuals 
were censored at the time of loss to follow-up, consented 
withdrawal, drug switching from initial treatment to another, 
being event-free at the end of follow-up period, or death 
(in the case of non-fatal outcomes)—whichever came first. 
Univariable and multivariable time-to-event analyses were 
used to identify risk factors associated with systemic safety 
outcomes as well as to compare risk of SSAEs between the 
IVB and IVR groups. We assumed that patients went miss-
ing at random and treatment allocation between IVB and 
IVR is independent of the outcome of interest. Missing data 
were not imputed.
As the rates of specific SAEs were expected to be low, 
these SAEs were combined as composite outcomes. Only 
all-cause mortality, ATE, and non-fatal HF were assessed 
in time-to-event analyses. Moreover, some covariates were 
combined with the aim of achieving at least 5–10 events 
per variable (EPV) to minimize bias and variability of esti-
mates and unreliable results [42, 43]. Covariates included 
were: age at enrollment, sex (female vs male), NHI (non-
CSMBS vs CSMBS), comorbidity related to CV risk factors 
[number of the following comorbidities: diabetes (DM), HT, 
dyslipidemia (DLP), chronic kidney disease (CKD), IHD, 
and stroke], use of antiplatelet drugs (no vs yes), and groups 
of total number of intravitreal drug injections in any eyes 
before the end of the study (1–3 injections vs > 3 injections). 
Possible interactions between covariates were also consid-
ered in the model when the number of the events became 
sufficient.
The propensity score (PS) method was applied to mini-
mize selection bias due to the imbalance of measured base-
line covariates between the IVB and IVR groups. The PS is 
the probability of a participant being treated with a certain 
treatment given a set of covariates [44, 45]. The PS was cal-
culated by age group (aged 18–51, 52–59, and 60–97 years), 
sex, DM, HT, IHD, stroke, and CKD. The PS was included 
as a continuous covariate in the multivariable time-to-event 
models.
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Multiple models were constructed to determine the best 
fit for the data. These models included the multivariable 
Cox proportional hazards regression model, the Weibull 
proportional hazards model, Exponential model, and 
Gompertz model. Model adequacy for each model and the 
proportionality assumption for Cox proportional hazards 
regression model were also assessed. Ultimately, the final 
models were chosen based on the lowest Akaike Informa-
tion Criterion (AIC) value as that would suggest a better fit 
for the data [46]. The results from the selected models are 
presented as unadjusted and adjusted hazard ratios (aHR) 
with a 95% confidence interval (95% CI).
All statistical analyses were performed with STATA 
version 14.2 (StataCorp, College Station, TX), using a 
two-sided statistical significance level of 0.05.
3  Results
3.1  Participants
A total of 6379 patients were initially recruited (Fig. 1). 
However, four patients were excluded because they did 
not receive either IVB or IVR treatment on the enroll-
ment date, but the reasons were not recorded. Nineteen 
patients with a history of drug switching within 6 months 
before the study enrollment were also excluded (14 and 
5 patients had previously been treated with IVB and IVR 
before receiving IVR and IVB at enrollment, respectively). 
This reduced the total number to 6356 patients. Finally, 
two patients without post-baseline safety assessments 
were also excluded. As a result, the final analysis popula-
tion consisted of 5975 patients in the IVB group and 379 
patients in the IVR group.
3.2  Patient Characteristics
Demographics and baseline characteristics of the study 
cohort based on the drug groups are summarized in Table 1. 
Patients aged ≥ 65 years accounted for 30.1% of the cohort. 
Overall, patients in the IVR group were older than those in 
the IVB group. In the IVR group, the proportion of patients 
under the CSMBS was larger than patients under the UC and 
SSS. Other significant differences can be seen in the propor-
tion of patients with DM or CKD (Online Resource 1) and 
the use of antiplatelet drugs, which was greater in the IVB 
group than the IVR group. There was also a higher propor-
tion of IVR-treated patients who were diagnosed with IHD 
or stroke than in the IVB-treated group.
3.3  Treatment Pattern
Most patients received unilateral treatment during the 
6-month follow-up period (90.2 and 72.6% in the IVR and 
IVB groups, respectively), and about half of patients had 
previously received IVR or IVB treatment. The mean follow-
up times and standard deviation (SD) from the enrollment 
date until the end of the follow-up period, or death or drug 
switching of patients enrolled in the IVR and IVB groups 
were 161 ± 42 and 172 ± 29 days, respectively. The propor-
tion of patients who switched drugs from IVR to IVB (73 
of 379) was much higher than patients who switched from 
IVB to IVR (192 of 5975) during the entire follow-up. The 
rates of loss to follow-up were similar across both groups: 
565 of 5975 (9.5%) in the IVB group and 38 of 379 (10.0%) 
in the IVR group.
The mean ± SD of total drug injections during the follow-
up period of the IVR and IVB groups were 2.6 ± 1.6 and 
2.7 ± 1.9 injections, respectively, and the total number of 
injections in the IVR and IVB groups were 974 and 16,421 
injections, respectively. The number of topical antibiotics 
used after intravitreal injection was 932 (95.7% of total IVR 
injections) and 15,770 (96.0% of total IVB injections). The 
IVTs were performed at operating rooms for 10% of total 
injections (IVR = 73 vs IVB = 1671 injections) and non-
operating rooms including outpatient clinics for 90% of total 
injections (IVR = 893 vs IVB = 14,698 injections).
3.4  Ocular Event: Endophthalmitis
There were six treated eyes (0.08%) from six patients in 
the IVB group who contracted endophthalmitis, while there 
were no events observed in the IVR group. This serious ocu-
lar event developed within 1 month of intravitreal injection 
of the affected eyes in 4 out of the 6 patients (mean ± SD 
4.25 ± 0.96 days, or approximately 3–5 days). The fifth 
patient was diagnosed with postoperative endophthalmitis 
from cataract surgery, which occurred 73 days after IVB Fig. 1  Flow diagram of patient participation
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Table 1  Demographics and baseline characteristics by treatment group
Data are presented as number (percentage) unless otherwise indicated
Age variable had a skewed distribution which median ages (25th–75th percentile) for IVR and IVB groups were 68 (20–97) and 58 (18–94) 
years respectively. Non-CSMBS group included patients under the Universal Health Coverage Scheme (UC) and Social Security Scheme (SSS)
CNV choroidal neovascularization, CSMBS Civil Servant Medical Benefit Scheme, DME diabetic macular edema, IVB intravitreal bevacizumab, 
IVR intravitreal ranibizumab, nAMD neovascular age-related macular degeneration, NHI National Health Insurance scheme, PCV polypoidal 
choroidal vasculopathy, PDR proliferative diabetic retinopathy, RVO retinal vein occlusion
a Number of the following comorbid conditions: diabetes, hypertension, dyslipidemia, chronic kidney disease, ischemic heart disease, and stroke
b Recent stroke or endophthalmitis were defined as a hospitalization due to stroke or endophthalmitis within 6 months prior to enrollment date
c Total 8027 treated-eyes (IVR = 416 versus IVB = 7611)
Demographic variables Ranibizumab (n = 379) Bevacizumab (n = 5975)
Age (years)
 Mean age ± SD 66 ± 13 58 ± 12
 Aged < 65 159 (42.0%) 4238 (70.9%)
 Aged ≥ 65 (elderly) 220 (58.0%) 1715 (28.7%)
 Missing values 0 22 (0.4%)
Sex
 Female 172 (45.4%) 3182 (53.3%)
 Male 207 (54.6%) 2793 (46.7%)
NHI
 Non-CSMBS 109 (28.8%) 4558 (76.3%)
 CSMBS 178 (47.0%) 783 (13.1%)
 Missing values 92 (24.3%) 634 (10.6%)
Smoking status
 Non-smokers 342 (90.2%) 5382 (90.1%)
 Smokers 35 (9.2%) 580 (9.7%)
 Missing values 2 (0.5%) 13 (0.2%)
Comorbidities
 No comorbid condition 79 (20.8%) 796 (13.3%)
 Had at least one comorbidity 300 (79.2%) 5179 (86.7%)
 Mean ± SD  (conditionsa) 2 ± 1 2 ± 1
Concomitant medicines
 Anticoagulants
  No 369 (97.4%) 5887 (98.5%)
  Yes 7 (1.9%) 66 (1.1%)
  Missing values 3 (0.8%) 22 (0.4%)
 Antiplatelet drugs
  No 247 (65.2%) 3537 (59.2%)
  Yes 129 (34.0%) 2413 (40.4%)
  Missing values 3 (0.8%) 25 (0.4%)
History of IVR and IVB treatment
 IVB and IVR naïve 160 (42.2%) 3096 (51.8%)
 IVB or IVR experienced 219 (57.8%) 2879 (48.2%)
Recent  strokeb
 No 379 (100.00%) 5974 (99.98%)
 Yes 0 1 (0.02%)
Recent  endophthalmitisb
 No 379 (100.00%) 5973 (99.97%)
 Yes 0 2 (0.03%)
Retinal diseases (treated-eye)c
 nAMD and CNV 136 (32.7%) 666 (8.8%)
 PCV 103 (24.8%) 641 (8.4%)
 DME 50 (12.0%) 2896 (38.1%)
 RVO 66 (15.9%) 808 (10.6%)
 PDR and related complications 37 (8.9%) 1891 (24.8%)
 Others 24 (5.8%) 706 (9.3%)
 Missing values 0 (0.0%) 3 (0.04%)
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injection. The last case was admitted due to occurrence of 
endophthalmitis 49 days after the IVB injection. In three of 
the six patients, visual acuity was 20/40, 20/100, and 6/12 
prior to developing endophthalmitis. However, even though 
they received endophthalmitis therapy, visual acuity for 
these three eventually declined to no light perception (NLP).
Results from the gram-stain and microbiological culture 
of vitreous fluid were available for only three patients who 
developed endophthalmitis. Gram-stain revealed gram-pos-
itive cocci for these three cases. The vitreous cultures iden-
tified coagulase-negative Staphylococci for the two cases 
while the result was not reported for one case.
3.5  SSAEs
Non-fatal strokes occurred in only 16 of the 5975 patients 
(0.27%) in the IVB group. The overall rate of mortality from 
any cause was 1.07%, which comprised 2 of the 379 IVR-
treated patients (0.53%) and 66 of the 5975 IVB-treated 
patients (1.10%). The rates of individual SAEs of inter-
est during the 6-month follow-up period ranged from 0 to 
1.21%; rates between the drug groups were similar (Table 2). 
Among SAEs of interest, there were only two patients in the 
IVR group who experienced acute subendocardial myocar-
dial infarction and congestive heart failure (CHF), respec-
tively. Non-fatal MI or IHD occurred in 20 patients (0.33%) 
in the IVB group. The proportions of patients who experi-
enced vascular death, cardiovascular events (ATE or HF), 
VTE, and one or more non-fatal SSAEs in the IVB group 
were higher than the rates of the IVR group.
There was no significant increase in rates of all-cause 
mortality, ATE, and non-fatal HF when comparing the risk 
profiles between patients treated with IVB and IVR. The 
unadjusted HR (95% CI) for risks of all-cause mortality, 
ATE, and non-fatal HF in the treatment groups were 1.96 
(95% CI 0.48–8.01), 2.70 (95% CI 0.37–19.60), and 4.23 
(95% CI 0.59–30.42), respectively.
The final multivariable models of the outcomes consid-
ered only the main effects to avoid the risk of overfitting 
when including interactions as well as variables with very 
low counts. After adjustment, the aHRs were not statis-
tically significantly different between the IVB and IVR 
groups (Table 3). The aHR values of the treatment group 
for all-cause mortality, ATE, and non-fatal HF were 1.8 
Table 2  Serious adverse events within 6 months of enrollment
Data were presented as number (percentage). Events in the same SAE category of each affected patient were counted only once. Vascular death 
comprises deaths due to stroke, IHD, and MI. Arterial thrombotic event defined as patients who experienced non-fatal MI/IHD, non-fatal stroke, 
or vascular death
GI gastrointestinal, IHD ischemic heart disease, MI myocardial infarction
a Composite outcomes
b Treated-eyes of IVR and IVB were 416 and 7611, respectively
c Total number of IVT during 6 months and have no drug switching was 17,395 (IVR 974 and IVB 16,421 injections)
Safety events Ranibizumab (n = 379) Bevacizumab (n = 5975)
Number of 
events
Affected patients Number of 
events
Affected patients
Serious systemic events
 All-cause mortality 2 2 (0.53%) 66 66 (1.10%)
 Arterial thrombotic  eventsa 1 1 (0.26%) 57 46 (0.77%)
  Non-fatal MI/IHD 1 1 (0.26%) 27 20 (0.33%)
  Non-fatal stroke 0 0 (0.00%) 17 16 (0.27%)
  Death from vascular  causesa 0 0 (0.00%) 13 13 (0.22%)
 Arterial thrombotic events or heart  failurea 2 2 (0.53%) 146 111 (1.86%)
  Heart failure 1 1 (0.26%) 89 72 (1.21%)
 Venous thrombotic  eventsa 0 0 (0.00%) 1 1 (0.02%)
  Pulmonary embolism 0 0 (0.00%) 1 1 (0.02%)
 Hospital admission for GI hemorrhage /perforation 0 0 (0.00%) 6 6 (0.10%)
 Transient ischemic attack 0 0 (0.00%) 2 2 (0.03%)
  ≥ 1 non-fatal serious systemic  eventsa – 2 (0.53%) – 109 (1.82%)
Serious ocular event: endophthalmitis
 Per persons 0 0 (0.00%) 6 6 (0.10%)
 Per treated-eyesb 0 0 (0.00%) 6 6 (0.08%)
 Per  injectionc 0 0 (0.00%) 6 6 (0.04%)
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(95% CI 0.2–13.2), 1.7 (95% CI 0.2–12.5), and 1.4 (95% 
CI 0.2–9.9), respectively. Patients with a higher number 
of comorbid conditions experienced increased risks of all-
cause mortality (aHR 1.6; 95% CI 1.2–2.0), ATE (aHR 
2.1; 95% CI 1.6–2.8), and non-fatal HF (aHR 2.2; 95% 
CI 1.7–2.8). The risk of ATE in male patients was 2.5 
times higher (aHR 2.5; 95% CI 1.3–4.7) than for female 
patients. In the case of non-fatal HF, CSMBS beneficiaries 
had lower risk than patients from other NHI schemes (aHR 
0.2; 95% CI 0.1–0.8). Patients who received a higher num-
ber of injections (> 3 injections) had statistically signifi-
cantly lower risks of all-cause mortality (aHR 0.08; 95% 
CI 0.02–0.34) and ATE (aHR 0.25; 95% CI 0.09–0.69) 
than those treated with ≤ 3 injections.
4  Discussion
4.1  Principal Findings
While off-label IVB may be a preferable alternative option 
to IVR in Thailand and LMICs, there were very few studies 
which have attempted to evaluate the safety of IVB treatment 
in these countries. Additionally, there was an insufficient 
number of large databases able to generate evidence through 
routine practice. To the best of our knowledge, this is the first 
large prospective observational study examining the safety 
of IVB compared with IVR in these settings. We primarily 
aimed to generate a safety profile of off-label IVB as part 
of a policy to establish a safety monitoring system after the 
inclusion of this medication into the NLEM. The results of 
this study supported the short-term safety of the off-label use 
of IVB in Thailand. Overall, the prevalence rates of systemic 
events and endophthalmitis were infrequent (ranging from 0 
to 1.21%). Cardiovascular events accounted for the largest 
proportion among non-fatal SSAEs of interest in both drug 
groups (HF: IVB 1.21% vs IVR 0.26%, and IHD/MI: IVB 
0.33% vs IVR 0.26%). We found that more than 80% of these 
cases had several comorbid conditions including IHD, and 
this confounder was adjusted in the multivariable models. 
Although the rate of the ocular SAE was lower than more 
severe SSAEs, low rates of SAEs could be seen in the entire 
cohort and were similar in both drug groups. We found that 
the IVB treatment did not significantly increase the risks of 
all-cause mortality, ATE, and non-fatal HF compared with 
the IVR treatment. The differences remained insignificant 
after adjusting for confounding factors, censored observa-
tions, and selection bias using multivariable time-to-event 
analyses with PS adjustment.
Table 3  Hazard ratios of patients who received IVB versus IVR treatment after adjusting for covariates and propensity scores
aHR adjusted hazard ratio, ATE arterial thrombotic event, CI confidence interval, Coef. standardized coefficient, CSMBS Civil Servant Medical 
Benefit Scheme, HF heart failure, IVB intravitreal bevacizumab, IVR intravitreal ranibizumab, NHI National health insurance scheme, SE stand-
ard error
a Covariate reference groups: IVR, female, other health insurance scheme (UC and SSS), 1–3 injections, and not use antiplatelet drugs
b Exponential model
c Weibull model
d Number of the following comorbid conditions: diabetes, hypertension, dyslipidemia, chronic kidney disease, ischemic heart disease, and stroke
e Continuous variable
Covariatea All-cause  mortalityb ATEc Non-fatal  HFc
Coef. SE aHR 95% CI Coef. SE aHR 95% CI Coef. SE aHR 95% CI
Treatment
 IVR vs IVB 0.58 1.02 1.78 0.24–13.18 0.51 1.03 1.66 0.22–12.47 0.30 1.01 1.35 0.19–9.88
Age (years)e 0.02 0.02 1.02 0.98–1.05 − 0.02 0.02 0.98 0.95–1.02 − 0.02 0.01 0.98 0.96–1.01
Sex
 Female vs male 0.48 0.26 1.62 0.97–2.69 0.90 0.33 2.46 1.29–4.67 − 0.22 0.25 0.80 0.49–1.30
NHI
 Others vs CSMBS − 0.22 0.41 0.80 0.36–1.80 − 1.07 0.61 0.34 0.10–1.14 − 1.63 0.72 0.20 0.05–0.81
Total drug injections
 1–3 vs > 3 injections − 2.48 0.72 0.08 0.02–0.34 − 1.40 0.52 0.25 0.09–0.69 − 0.47 0.30 0.62 0.35–1.12
Comorbiditiesd,e (conditions) 0.44 0.13 1.55 1.19–2.01 0.75 0.15 2.12 1.59–2.84 0.77 0.13 2.17 1.69–2.78
Use antiplatelet drugs
 No vs yes 0.03 0.27 1.03 0.61–1.75 0.60 0.35 1.82 0.91–3.64 0.48 0.27 1.61 0.95–2.73
Propensity  scoree 19.27 7.17 − 7.23 3.81 5.61 5.73
Constant − 30.63 7.47 − 7.01 4.38 − 19.36 6.08
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4.2  Comparison with Other Studies
Our results were consistent with published RCTs, meta-
analyses, and observational studies [16–18, 22–24, 27, 33, 
38, 47–49], showing that patients treated with IVB had low 
rates of serious ocular and systemic adverse events. We 
found slightly higher rates of anti-VEGF-associated systemic 
events in the IVB group compared to the IVR group, but 
these differences were not statistically significant.
Compared to two RCTs conducted in nAMD patients in 
the US and the UK (CATT and IVAN) [22, 27], our study 
observed outcomes within a shorter period while partici-
pants overall were younger with lower rates of recent vascu-
lar events. We found similar proportions of patients experi-
encing SAEs including all-cause mortality and ATE in both 
IVB and IVR groups, and the frequencies were lower than 
in those head-to-head trials. The CATT study revealed a 
higher percentage of patients with at least one SSAE in the 
IVB group [39.9 vs 31.7%; adjusted risk ratio (RR) 1.30; 
95% CI 1.07–1.57]. However, these events were not likely 
related to drug action on the VEGF pathway and the impact 
of different rates of TIA and MI history between the IVB 
and IVR groups at the baseline was not clearly explained 
[22]. A non-industry-funded RCT conducted by The Dia-
betic Retinopathy Clinical Research Network (DRCR.net) 
found similar risks of any Antiplatelet Trialists’ Collabora-
tion Event (i.e. non-fatal MI, non-fatal stroke, or vascular 
death) after adjusting for age, sex, hemoglobin A1c level at 
the baseline, diabetes type and time since diagnosis at the 
baseline, insulin use, prior coronary artery disease (CAD), 
prior MI, prior stroke, prior TIA, prior HT, and smoking 
status among DME patients treated with aflibercept (5%), 
bevacizumab (8%), and ranibizumab (12%) [49].
Poku et al. [16] reviewed 22 RCTs and 67 observational 
studies with a minimum of 10 participants (sample sizes 
ranged from 11–27,962 IVB-treated patients) and reported 
low rates of SAEs but could not elucidate the relationship 
between IVB and those events. In comparison with studies 
included in this systematic review [16] and a safety review 
published in 2017 [33], our study found no excess ocular 
and systemic risks. Both reviews [16, 33] also highlighted 
the limitations of previous evidence. Randomized trials 
were underpowered to detect statistically significant dif-
ferences in rare SAEs and excluded patients at high cardio-
vascular risk, causing limited generalizability. Most of the 
existing observational studies had low quality and limita-
tions such as small sample sizes, ambiguous diagnostic cri-
teria, and poor reporting of study outcomes. Our study was 
designed as a prospective multicenter cohort study and the 
sample size was larger than most of the previous observa-
tional studies. Most of these studies were descriptive stud-
ies with no comparator and had retrospective study designs. 
They also had small sample sizes and poor reporting on 
handling potential confounders except in a few of the large 
observational studies using healthcare databases in devel-
oped countries [33]. A large retrospective cohort study 
[47] using the Medicare database included 38,718 and 
19,026 patients with nAMD in the IVB and IVR groups, 
respectively. This study found a significantly higher risk 
of stroke in the IVB group compared to the IVR group 
in the primary analysis. However, a higher SES might 
increase the probability of receiving IVR and is vulnerable 
to selection bias. After further adjustment for SES, there 
were no differences in the risks of mortality (aHR 1.10; 
95% CI 0.85–1.41), MI (aHR 0.87; 95% CI 0.53–1.41), 
bleeding (aHR 1.01; 95% CI 0.80–1.28), and stroke (aHR 
0.87; 95% CI 0.61–1.24) in the IVR group compared with 
the IVB group. A population-based nested case–control 
study [18] used linked data from Ontario’s healthcare data-
bases (n = 91,378) and matched patients based on age, sex, 
history of outcomes, and DM. The results reaffirmed that 
there were no differences in risk of ischemic stroke (aHR 
1.03; 95% CI 0.67–1.60), acute MI (aHR 1.23; 95% CI 
0.85–1.77), VTE (aHR 0.92; 95% CI 0.51–1.69), and CHF 
(aHR 1.35; 95% CI 0.93–1.95) in the IVB group compared 
with the IVR group. Although these studies [18, 47] had 
large sample sizes and described their attempts to deal with 
potential confounding factors, they did not take the effect 
of repeated doses of drugs into account. Moreover, SAEs 
and death outside of hospitals were not captured using 
these databases and their results may not be generalized to 
the patient population not covered in the databases.
The multivariable parametric models in our study showed 
that the increase in the number of comorbid conditions was 
associated with increased risks of all-cause mortality, ATE, 
and non-fatal HF. This finding emphasizes the importance 
of taking these cardiovascular risk factors into account for 
high-risk patients.
We found that patients who received more than three 
injections of IVB or IVR had lower rates of all-cause 
mortality and ATE. These decreased risks disagreed with 
biological plausibility. If thromboembolic risk caused 
by systemic VEGF inhibition is associated with a dose-
response relationship, the results in the present analysis 
do not support this assumption. This trend is similar to the 
pooled results from the CATT [26] and IVAN [27] studies. 
The group treated with less frequent injections either as-
needed or via treatment discontinuation after three consec-
utive monthly injections had a significant 51% lower risk 
of death [pooled odds ratio (OR) 0.49; 95% CI 0.27–0.86] 
[27]. Etminan et al found no significant different risk of MI 
(adjusted RR 0.71; 95% CI 0.41–1.22) and stroke (adjusted 
RR 0.81; 95% CI 0.39–1.65) between nAMD patients who 
received a higher number of IVB injections and patients 
who received less than the median number of injections for 
each outcome [48].
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In the case of ocular safety, the overall prevalence of 
endophthalmitis found in our study was 0.03% per injec-
tion (0.09% per person). This low rate was in line with 
findings of other studies conducted in the Thai setting [37, 
39, 50], previous observational studies [16], and the CATT 
study [22]. We could not perform formal statistical tests to 
investigate the relationship between endophthalmitis and 
IVB preparation or other potential risk factors due to the 
limited number of events. In this study, there was one case 
that could be confirmed as postoperative endophthalmitis 
from cataract surgery. Thus, it was clear that this case was 
not related to either a drug-related or procedure-related 
complication. Moreover, we found that there was no occur-
rence of endophthalmitis in other patients from the same 
study site who received IVB from the same repackaged lot, 
the same dates of preparation and expiration after repack-
aging, and the same injection date and were injected by 
the same physicians at the same injection room as those 
endophthalmitis cases. Therefore, it might be assumed 
that the risk of endophthalmitis might be associated with 
patient-related factors rather than drug-related and proce-
dure-related factors.
4.3  Limitations of Study
First, this study was vulnerable to potential confounding 
and selection bias due to the nature of non-randomized 
studies. Statistical methods were conducted to account 
for this issue. Where the number of events was sufficient, 
multivariable analyses in conjunction with the PS method 
were performed to address any interference effects from 
well-established risk factors of cardiovascular disorders 
and imbalance of demographics and baseline character-
istics. Second, our results represented only short-term 
safety profiles. We considered that 6 months of safety 
observation would be sufficient to capture the safety of 
IVB and IVR based on pharmacokinetic data [51] and 
time to develop SSAEs reported by previous studies [24, 
52] together with opinion from retina specialists. Third, 
adverse events or other SAEs were beyond the scope of 
this study. Furthermore, we did not assess the safety of 
aflibercept, the VEGF trap, because it was introduced into 
Thailand approximately around the end of our data collec-
tion period. Lastly, the small number of participants in the 
IVR group and small number of events in this group led 
to imprecise estimates with wide 95% CIs, which did not 
allow us to conduct a comparative assessment for individ-
ual SSAEs of interest between IVB and IVR treatments. 
Moreover, none of the endophthalmitis cases was found in 
the IVR group. This study could not prove the absence of 
the potential difference in endophthalmitis rates between 
the IVB and IVR groups. This result should, therefore, be 
interpreted with caution.
4.4  Conclusions and Policy Implications
This research provides safety evidence supporting the inclu-
sion of off-label IVB into the Thai NLEM and the WHO 
EML. According to the nature of the observational study, 
our findings can be generalized to treatments for a wide 
variety of patient characteristics including patients at high 
risk in real clinical settings. Moreover, the results also dem-
onstrated that both IVB and IVR have been used not only 
for nAMD and DME, but also for non-FDA approved indi-
cations in routine practice; however, IVR was likely to be 
prescribed according to FDA-approved indications. Since 
published RCTs were mainly conducted in patients with 
nAMD, DME, and RVO, the findings from this study may 
be used as supplementary evidence for the safety of IVB in 
other retinal conditions.
It also provides the information about endophthalmitis in 
the Thai context that differs from the clinical environment 
in developed countries. Moreover, the findings reveal the 
importance of proper management for patients at risk such 
as patient counseling or consideration of alternative treat-
ments which do not increase the risk of such adverse events.
Apart from the safety issue, it could be clearly seen that 
the extent of off-label IVB usage was much higher than IVR 
(IVB 94% vs IVR 6%) and has been increasing since the 
NLEM policy was implemented. According to the NHSO’s 
report presented at The Prince Mahidol Award Conference 
2016, the number of new IVB-treated patients with nAMD 
and DME in 2015 had increased by a factor of 1.6 compared 
to the number in 2013, and the cumulative number of these 
patients and total injections were 11,306 patients and 40,911 
injections over 3 years after the policy launch.
As far as the NHI is concerned, CSMBS insurers received 
IVR treatment approximately 4.4 times more than IVB treat-
ment. A possible reason might be related to the coverage of 
the pharmaceutical benefit packages as only the CSMBS 
provides full reimbursement for IVR therapy when the ben-
eficiary has been diagnosed with FDA-licensed indications. 
In contrast, non-CSMBS patients must either pay out-of-
pocket for this expensive drug or use alternative treatment 
options including IVB and non-pharmacological interven-
tions. The number of IVR-treated patients in Thai public 
hospitals was small and may decrease over time because of 
its high cost, implementation of the NLEM policy, and use 
of aflibercept. Aflibercept is the newest FDA-approved anti-
VEGF agent for treating nAMD, DME, and RVO and its cost 
in Thailand is as high as ranibizumab. Thus, IVB remains 
the most affordable option.
Based on the cumulative safety evidence and our find-
ings, it may be concluded that the risks of IVB were low in 
terms of anti-VEGF-associated SAEs and endophthalmitis 
when properly compounded as a single dose for ocular use. 
The available evidence also supported the notion that IVB 
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and IVR treatments had similar efficacy and safety profiles. 
It is likely that findings from further research with longer 
follow-up periods and larger sample sizes might not differ 
from currently available evidence.
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